Legal Issues of Cardiovasc as Quality Drug Patented Product Based on Pharmaceutical Formulations Using Spectrophotometric Validation for Healthcare Corporate Governance

Abstract

Purpose: Cardiovasc is the patented product name of Amlodipine besylate. Its intended design is aimed for vasodilatory action primarily used in treating stable and variant angina, and hypertension. This study aims to validate the linearity of absorbance of the reference standard with Cardiovasc drug concentration. Moreover, the drug concentration elucidation from the samples aims to quantitate the correlation of the marketed patented drug for commercial use as possible source of environmental pollutants known as greenhouse gases. 
 Methodology: Ultraviolet-visible spectroscopy is used to measure the absorbance of the drug samples, Amlodipine besylate reference standard and Cardiovasc, for validation of linearity with drug concentration using the electron excitement from HOMO to LUMO of anti-bonding energy levels for catalytic analysis of drug concentration. Interaction with uncertainties, risks, and capabilities is a tool for decision making of health effects and economic impacts to sustainable development.
 Findings: The results from Ultraviolet-visible spectroscopy shows that minimal drug concentration exposed as discharge to the environment will not exhibit any linear correlation as significant contributor of environmental pollutants. The commercial drug, Cardiovasc, follows the second range of Amlodipine besylate reference standard, hence, Cardiovasc effluents play a critical role to the quality design of marketed drug in terms of medical research methods as this procedure is done as exclusion to the acquired drug patentability intended to exercise their healthcare corporate governance as fulfillment of monetary goals in business ethics of sustainable development.
 Recommendations: This legal validation highlights the significance of linear correlation of patented drug to environmental effects as social responsibility of corporate healthcare governance. Hence, the International Trade Law enables the marketed drug product to perform its intended action as well as to advocate sustainable development goals as “commercial” in nature. As the European Patent Commission clearly states that medical research methods are excluded from the patentability coverage of drug product, this paper strongly recommends innovation of tools, engineering on eradicating greenhouse gases as sources of environmental pollutants that play a crucial factor to climate change.